About this trial
The current guideline emphasizes fluid resuscitation as the mainstay of initial management for septic shock. Albumin has the oncotic activity to maintain intravascular volumes with additional beneficial properties in sepsis. Prior studies showed that the replacement of albumin might have survival advantages in patients with septic shock. The investigators aim to assess whether the early administration of albumin with crystalloid as initial fluid resuscitation improves survival in patients with septic shock compared to resuscitation without albumin.
Eligibility criteria
Qualifiers
Adult patients (≥ 18 years) who visit an ED directly and are suspected of sepsis with shock
Shock is defined as hypotension (mean arterial blood pressure (MAP) < 65 or systolic blood pressure < 80) and tissue hypoperfusion such as an initial serum lactate level ≥ 4 mmol/dL.
Disqualifiers
patients who are transferred from another hospital after initial fluid administration
patients who have set limitations on treatment (e.g. patients with a signed do-not-resuscitate order)
patients with moribund conditions with life expectancy less than 28 days due to secondary diseases or advanced malignant disease and palliative situations with life expectancy less than 6 months
patients who have been administered albumin before enrollment
Trial design
Treatments tested in this trial
- Treatment
- Placebo
Treatment groups
Sponsors and collaborators
Asan Medical Center
Lead sponsor
Samsung Medical Center
Collaborator
Gangnam Severance Hospital
Collaborator
Chungnam National University Hospital
Collaborator
Seoul National University Hospital
Collaborator
Seoul National University Bundang Hospital
Collaborator
SMG-SNU Boramae Medical Center
Collaborator
Hanyang University
Collaborator
Korea University Ansan Hospital
Collaborator